Literature DB >> 22788762

Synthetic lethality to overcome cancer drug resistance.

L Porcelli1, A E Quatrale, P Mantuano, N Silvestris, A E Brunetti, H Calvert, A Paradiso, A Azzariti.   

Abstract

A large body of evidence point out that the onset of synthetic lethality may provide a useful tool for amplifying the efficacy of drugs in anticancer regimens, to uncover interdependence between genes and to identify predictive factors that would be extremely useful to guide in the selection of more effective targeted drugs and drug combinations for each patient. Here, we provide an overview on the exploitation of synthetic lethality to overcome drug resistance to conventional chemotherapy in several types of solid tumors. We report recent findings on cellular markers and gene mutations which are specifically essential for the viability of cancer cells and for resistance to chemotherapeutics. In addition, new molecularly targeted strategies to overcome drug resistance are suggested.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22788762     DOI: 10.2174/092986712802002563

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  8 in total

1.  Optimize radiochemotherapy in pancreatic cancer: PARP inhibitors a new therapeutic opportunity.

Authors:  Letizia Porcelli; Anna E Quatrale; Paola Mantuano; Maria G Leo; Nicola Silvestris; Jean F Rolland; Enza Carioggia; Marco Lioce; Angelo Paradiso; Amalia Azzariti
Journal:  Mol Oncol       Date:  2012-10-29       Impact factor: 6.603

2.  Regulation of MRP4 Expression by circHIPK3 via Sponging miR-124-3p/miR-4524-5p in Hepatocellular Carcinoma.

Authors:  Haihong Hu; Yu Wang; Zhiyuan Qin; Wen Sun; Yanhong Chen; Jiaqi Wang; Yingying Wang; Jing Nie; Lu Chen; Sheng Cai; Lushan Yu; Su Zeng
Journal:  Biomedicines       Date:  2021-04-30

3.  RNA interference screening identifies a novel role for PCTK1/CDK16 in medulloblastoma with c-Myc amplification.

Authors:  Paulina Ćwiek; Zaira Leni; Fabiana Salm; Valeriya Dimitrova; Beata Styp-Rekowska; Gianpaolo Chiriano; Michael Carroll; Katrin Höland; Valentin Djonov; Leonardo Scapozza; Patrick Guiry; Alexandre Arcaro
Journal:  Oncotarget       Date:  2015-01-01

4.  Multiple myeloma-associated hDIS3 mutations cause perturbations in cellular RNA metabolism and suggest hDIS3 PIN domain as a potential drug target.

Authors:  Rafal Tomecki; Karolina Drazkowska; Iwo Kucinski; Krystian Stodus; Roman J Szczesny; Jakub Gruchota; Ewelina P Owczarek; Katarzyna Kalisiak; Andrzej Dziembowski
Journal:  Nucleic Acids Res       Date:  2013-10-22       Impact factor: 16.971

Review 5.  Short-term Intervention to Revert Premalignant Lesions as Strategy to Prevent Gastrointestinal Cancers.

Authors:  Young-Min Han; Jong-Min Park; Ho-Jae Lee; Eun-Hee Kim; Ki Baik Hahm
Journal:  J Cancer Prev       Date:  2013-12

6.  Induction of c-Cbl contributes to anti-cancer effects of HDAC inhibitor in lung cancer.

Authors:  Tzu-Tang Wei; Yu-Chin Lin; Pei-Hua Lin; Jin-Yuan Shih; Chia-Wei Chou; Wei-Jan Huang; Yu-Chih Yang; Pei-Wen Hsiao; Ching-Chow Chen
Journal:  Oncotarget       Date:  2015-05-20

Review 7.  New frontiers in the treatment of colorectal cancer: Autophagy and the unfolded protein response as promising targets.

Authors:  Pooneh Mokarram; Mohammed Albokashy; Maryam Zarghooni; Mohammad Amin Moosavi; Zahra Sepehri; Qi Min Chen; Andrzej Hudecki; Aliyeh Sargazi; Javad Alizadeh; Adel Rezaei Moghadam; Mohammad Hashemi; Hesam Movassagh; Thomas Klonisch; Ali Akbar Owji; Marek J Łos; Saeid Ghavami
Journal:  Autophagy       Date:  2017-02-23       Impact factor: 16.016

8.  Epistasis in genomic and survival data of cancer patients.

Authors:  Dariusz Matlak; Ewa Szczurek
Journal:  PLoS Comput Biol       Date:  2017-07-05       Impact factor: 4.475

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.